Mwandishi:
Mhariri:
Imeboershwa:
ULY CLINIC
ULY CLINIC
17 Februari 2026, 14:31:27

Erysipelas
Erysipelas is an acute superficial bacterial infection of the upper dermis and superficial lymphatics, most commonly caused by β-hemolytic streptococci, particularly Streptococcus pyogenes.
It is considered a more superficial and sharply demarcated form of cellulitis.The infection spreads rapidly through lymphatic channels, producing characteristic raised borders.
Most frequently affected sites:
Face (classically butterfly distribution)
Lower limbs (commonest overall)
Arms
Umbilical stump (neonates)
The disease has abrupt onset, marked systemic symptoms, and striking skin findings.
Etiology & Microbiology
Main pathogen
Streptococcus pyogenes
Less common organisms
Organism | Situation |
Group B, C, G streptococci | Elderly & diabetics |
Staphylococcus aureus | Secondary infection |
Gram-negative bacteria | Immunocompromised patients |
Pathophysiology
Entry through skin barrier defect
Fissures
Tinea pedis
Ulcers
Surgical wounds
Insect bites
Bacterial multiplication in superficial dermis
Lymphatic invasion
Causes raised sharply demarcated plaques
Release of streptococcal toxins
Fever and systemic toxicity
Inflammatory edema
Blistering and hemorrhage
Risk Factors
Local risk factors
Tinea pedis (most common portal of entry)
Chronic edema / lymphedema
Venous insufficiency
Skin trauma
Surgical wounds
Systemic risk factors
Diabetes mellitus
Obesity
Chronic kidney disease
Alcoholism
Immunosuppression
Elderly age
Malnutrition
Recurrence risk factors
Previous erysipelas
Persistent lymphatic damage
Chronic fungal infection of feet
Clinical Features
Prodrome (hours before skin lesions)
Fever
Chills
Malaise
Headache
Vomiting (children)
Local Skin Findings
Rapidly spreading erythematous plaque
Raised, sharply demarcated border
Warm and tender
Edematous swelling
Shiny tight skin
Burning pain
Advanced Local Findings
Superficial blistering (bullae)
Petechiae or superficial hemorrhage
Lymphangitis streaking
Regional lymphadenopathy
Systemic manifestations
High fever (38–40°C)
Tachycardia
Leukocytosis
Toxic appearance
Diagnostic Criteria
Diagnosis is primarily clinical.
Major diagnostic features
Acute onset fever
Raised well-demarcated erythematous plaque
Tender swelling
Supportive features
Regional adenopathy
Blistering due to edema
Superficial hemorrhage
Differential Diagnosis
Condition | Distinguishing Feature |
Cellulitis | Ill-defined borders, deeper infection |
Contact dermatitis | Itchy, not painful, no fever |
Deep vein thrombosis | Limb swelling without erythema margin |
Necrotizing fasciitis | Severe pain out of proportion, crepitus |
Herpes zoster | Vesicles along dermatome |
Investigations
Usually not required for uncomplicated erysipelas.
Laboratory tests
Test | Finding |
CBC | Leukocytosis |
CRP/ESR | Elevated |
Blood cultures | Positive in severe cases |
Microbiology
Skin cultures rarely useful
Aspiration culture occasionally performed in severe disease
Imaging
Ultrasound: rule out abscess
Doppler: rule out DVT
CT/MRI: suspected necrotizing infection
Treatment
A. Non-Pharmacological Management
Bed rest
Elevation of affected limb
Compression therapy after acute phase
DVT prophylaxis (if immobilized)
B. Local Therapy
Weak potassium permanganate soaks (0.025%) twice daily
Reduce bacterial load and exudate
Topical options:
Silver sulfadiazine cream
Mupirocin 2%
Fusidic acid 2%
(Topicals are adjuncts — NOT definitive treatment)
C. Systemic Antibiotic Therapy (Main Treatment)
First-line (Streptococcal coverage)
Phenoxymethylpenicillin
Adults: 250–500 mg PO every 6 hours × 5–7 days
Children: 25 mg/kg every 6 hours
OR
Flucloxacillin
Adults: 500 mg PO every 6 hours × 5–7 days
Children: 25–50 mg/kg every 6 hours
Severe infection (hospitalized)
IV benzylpenicillin or ceftriaxone (not listed but clinically standard)
D. Surgical Treatment
Indicated if complications develop:
Secondary abscess → incision & drainage
Necrosis → surgical debridement
Complications
Local complications
Abscess formation
Skin necrosis
Ulceration
Chronic lymphedema
Recurrent erysipelas
Systemic complications
Bacteremia
Septic arthritis
Endocarditis
Post-streptococcal glomerulonephritis
Toxic shock syndrome
Prevention
Treat tinea pedis aggressively
Proper wound care
Control edema (compression stockings)
Skin moisturization to prevent fissures
Weight reduction
Glycemic control in diabetics
Recurrent erysipelas prophylaxis
Long-term penicillin prophylaxis may be required in frequent recurrence.
Patient Education
Seek urgent care if:
Fever >38.5°C
Rapid spread of redness
Severe pain
Blistering or black discoloration
Confusion or weakness
Do NOT:
Massage affected area
Apply irritant chemicals
Walk excessively during acute phase
Prognosis
Scenario | Outcome |
Early treated | Rapid improvement within 48–72 hrs |
Delayed treatment | Recurrence & lymphatic damage |
Recurrent disease | Chronic lymphedema |
References
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for skin and soft tissue infections. Clin Infect Dis.
World Health Organization. Guidelines for the management of common skin infections. Geneva: WHO.
Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 7th ed.
Fitzpatrick TB, et al. Fitzpatrick’s Dermatology in General Medicine. 9th ed.
Andrews GC, et al. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier.
Oxford Handbook of Infectious Diseases and Microbiology. Oxford University Press.
CDC. Group A Streptococcal Skin Infection Guidelines.
IDSA Clinical Practice Guideline for Skin and Soft Tissue Infections.
NICE Guideline: Cellulitis and Erysipelas antimicrobial prescribing.
WHO Essential Medicines List and Antibiotic Recommendations.
Imeandikwa;
3 Novemba 2020, 09:13:42
